secwatch.observer — SEC 8-K summary
======================================

Issuer:     REGENERON PHARMACEUTICALS, INC. (REGN)
CIK:        0000872589
Form:       8-K
Filed at:   2025-01-13T23:59:59+00:00
Accession:  0001104659-25-002826
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Regeneron reports 2024 prelim EYLEA sales $6B; Libtayo >$1B; Dupixent >1M patients; pipeline updates
--------------------------------------------------------------------------------

- EYLEA HD and EYLEA aggregate U.S. net sales $6B for 2024 (+1% YoY); Q4 combined $1.5B (EYLEA HD $305M).
- Libtayo exceeded $1B in 2024 annual net sales; Phase 3 adjuvant CSCC shows 68% risk reduction vs placebo.
- New Truveta collaboration to sequence up to 10M additional individuals; RGC has sequenced ~3M people.
- Preliminary Q4 2024 IPR&D charge ~$14M pre-tax, expected to impact GAAP and non-GAAP EPS by ~$0.11.
- Dupixent now used by over 1M patients globally; linvoseltamab BLA resubmitted with launch anticipated mid-2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/872589/000110465925002826/0001104659-25-002826-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/872589/000110465925002826/tm253014d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-002826

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer